OrganOx, the leading company in ex-vivo warm perfusion of donor livers prior to transplantation, is delighted to announce completion of enrolment in its pivotal European clinical study. The study, the world’s first multi-center randomised clinical trial to compare the benefits of warm liver perfusion with the currently accepted practice of cold storage, comprised 220 liver transplants at 7 European centres.
OrganOx CEO, Dr Les Russell commented:
This is a significant milestone for OrganOx. Study recruitment completed 3 months earlier than expected which is a testament to the commitment of the transplant centres and their experiences with our device. We look forward to the results of the study and thank all the centres and support staff for their enthusiasm in participating in this exciting trial. We are also grateful to Prof Ploeg and the COPE consortium members for their energy and commitment and to the European Union for their financial support through the 7th framework programme for research and development.
The CE marked OrganOx metra is a fully automated and transportable device for ex-vivo normothermic perfusion and assessment of donor livers prior to transplantation. The metra, the result of 20 years of research, provides oxygen and nutrition to the donor liver at physiological flow rates, pressures and temperature.
Participating trial centres: Queen Elizabeth Hospital, Birmingham; King’s College Hospital, London; Royal Free Hospital, London; Addenbrookes Hospital, Cambridge; University Hospitals Leuven, Leuven (BE); Universitätsklinikum Essen, Essen (DE); Fundació Clinic per a la Recerca Biomèdica, Barcelona (ES).